| LYB |
Report |
Adjusted EPS (2026Q2) |
BEAT |
pred ~$3.60 vs. cons $3.44 |
MEDIUM |
| LYB |
Report |
Adjusted EBITDA (2026Q2) |
BEAT |
pred ~$1.88B vs. cons $1.80B |
MEDIUM |
| LYB |
Report |
Revenue (2026Q2) |
BEAT |
pred ~$9.36B vs. cons $9.21B |
MEDIUM |
| LYB |
Guide |
Implicit adjusted EBITDA outlook |
LOWER |
guide ~$1.50B vs. cons $1.60B (2026Q3) |
MEDIUM |
| LYB |
Guide |
Implicit adjusted EPS outlook |
LOWER |
guide ~$2.45 vs. cons $2.65 (2026Q3) |
MEDIUM |
| LYB |
Guide |
Incremental cash-improvement target |
UNCHANGED |
guide ~$500M vs. cons $500M (FY2026) |
HIGH |
| LYB |
Return |
Day-1 residual (stock − beta × S&P 500) |
-1.5% |
— |
MEDIUM |
| LYB |
Return |
5-day cumulative residual |
-3.5% (FOLLOW-THROUGH) |
Q2 upside is largely anticipated and temporary peak-margin benefits are discounted; implicit 2026Q3 adjusted EPS of ~$2.45 versus consensus ~$2.65 should trigger out-period estimate cuts despite the reported beat. |
MEDIUM |